Press Detail





Biotest AG: Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share

Biotest AG / AGM/EGM

06.05.2010 18:24

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Annual General Meeting 2010: Shareholders Approve Dividend of  EUR 0.34 per
Ordinary Share and EUR 0.40 per Preference Share


Dreieich/ Frankfurt am Main, May 6, 2010 - Shareholders of Biotest AG with
81.7% of shareholder present, approved  a dividend of EUR 0.34 per ordinary
share for 2009 and a dividend of EUR 0.40 per preference share at the
company's Annual General Meeting held today in Frankfurt/ Main. This
corresponds to a total dividend payout of approx. EUR 4.3 million.

The Annual General Meeting approved by a large majority the creation of
authorized capital stock with subscription right (agenda item 8) and the
creation of authorised capital stock with the possibility to exclude the
subscription right (agenda item 9).

At the subsequent meeting of preferred shareholders, however, with 15.9% of
shareholders present, the creation of authorised capital stock with the
possibility to exclude the subscription right failed to achieve the
required three-quarters majority. Consequently, the creation of authorised
capital stock with subscription right remains.

In addition, the Annual General Meeting approved the ratification of the
acts of management of the members of the Management Board and of the
members of the Supervisory Board for 2009 and approved all other proposals
put forward by the Management Board and Supervisory Board.
About 130 shareholders and guests took part in the Annual General Meeting. 

The full version of Prof. Dr. Gregor Schulz's speech is available online
at:
http://www.biotest.de/ww/en/pub/investor_relations/shareholders_meeting.cfm


Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
 

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.


Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, 
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406, 
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
www.biotest.de


06.05.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Deutschland
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------